The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association…
By C. Vlachopoulos, P. Xaplanteris, V. Aboyans, M. Brodmann, R. Cífková, F. Cosentino, M. De Carlo, A. Gallino, U. Landmesser, S. Laurent and 17 more. Atherosclerosis, 2015
714 citations recorded by the source corpus.
While risk scores are invaluable tools for adapted preventive strategies, a significant gap exists between predicted and actual event rates. Additional tools to further stratify the risk of patients at an individual level are biomarkers. A surrogate endpoint is a biomarker that is intended as a substitute for a clinical endpoint. In order to be considered as a surrogate endpoint of cardiovascular events, a biomarker should satisfy several criteria, such as proof of concept, prospective validation, incremental value, clinical utility, clinical outcomes, cost-effectiveness, ease of use, methodological consensus, and reference values. We scrutinized the role of peripheral (i.e. not related to coronary circulation) noninvasive vascular biomarkers for primary and secondary cardiovascular disease prevention. Most of the biomarkers examined fit within the concept of early vascular aging. Biomarkers that fulfill most of the criteria and, therefore, are close to being considered a clinical surrogate endpoint are carotid ultrasonography, ankle-brachial index and carotid-femoral pulse wave velocity; biomarkers that fulfill some, but not all of the criteria are brachial ankle pulse wave velocity, central haemodynamics/wave reflections and C-reactive protein; biomarkers that do no not at present fulfill essential criteria are flow-mediated dilation, endothelial peripheral arterial tonometry, oxidized LDL and dysfunctional HDL. Nevertheless, it is still unclear whether a specific vascular biomarker is overly superior. A prospective study in which all vascular biomarkers are measured is still lacking. In selected cases, the combined assessment of more than one biomarker may be required.
Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/c8bf65858e3529e95249020c598fb1c18fa27945
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. (2019, neutral): “A recent position paper by the European Society of Cardiology Working Group on Peripheral Circulation 32 concluded that FMD is principally a valuable research tool.”
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “CIMT is reduced with statins in RCTs,(410,411) yet the predictive role of this biomarker (but not of carotid plaque) is somewhat compromised in light of recent data.(60) Modest regression of carotid atherosclerosis with niacin in most (but not all) imaging studies was not supported by clinical benef”